Announcements
- Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma
- Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities
- Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors
- Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
Key statistics
On Friday, Philogen SpA (78Q:STU) closed at 21.00, 0.00% below its 52-week high of 21.00, set on May 31, 2024.
52-week range
Open | 20.50 |
---|---|
High | 21.00 |
Low | 20.50 |
Bid | 20.50 |
Offer | 21.70 |
Previous close | 20.60 |
Average volume | 1.50 |
---|---|
Shares outstanding | 29.24m |
Free float | 10.97m |
P/E (TTM) | -- |
Market cap | 619.95m EUR |
EPS (TTM) | -0.1551 EUR |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼